We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics


Illumina develops, manufactures and markets integrated systems for the analysis of genetic variations and biological ... read more Featured Products: More products

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
05 Mar 2022 - 09 Mar 2022
Virtual Venue

Menstrual Blood Testing With Capture Sequencing Detects High-Risk Human Papillomavirus

By LabMedica International staff writers
Posted on 04 Jan 2022
Print article
Image: The 21 HPV GenoArray Diagnostic Kit for the rapid and accurate HPV genotyping macro array for 21 human papillomavirus identification (Photo courtesy of Hybribio Ltd)
Image: The 21 HPV GenoArray Diagnostic Kit for the rapid and accurate HPV genotyping macro array for 21 human papillomavirus identification (Photo courtesy of Hybribio Ltd)
Persistent infection of high-risk human papillomavirus (hrHPV) is associated with various HPV-related pre-cancers and cancers. In recent years, HPV testing has gradually become the primary method for cervical cancer screening.

Self-sampling HPV testing is a proposed alternative cervical cancer screening for avoiding stigma and improving participation. Most existing self-sampling HPV studies were based on various sampling brushes inserted into the vagina, and patients may experience discomfort during sampling. Compared with these methods, menstrual blood (MB) collection is associated with less stigma and pain.

Gynecologists at the Sun Yat-sen University (Guangzhou, China) and their colleagues recruited women who were premenopausal and had tested positive for hrHPV in the Central Hospital of Wuhan (Wuhan, China), from September 1, 2020, to April 1, 2021. Cervical smears were collected from recruited patients by an experienced gynecologist. Self-provided commercial sanitary pads were used to collect MB from enrolled patients. A total of 120 enrolled women with hrHPV (mean [SD; range] age, 33.9 [6.9; 20.0 -52.0] years) provided 137 sanitary pads.

A commercial Tiangen dried blood spot DNA extraction kit (Tiangen Biotech, Beijing, China) was used to extract MB DNA from sanitary pads. The concentration of DNA was confirmed using the Qubit 4.0 fluorometer and Qubit dsDNA high-sensitivity (HS) assay kit (Thermo Fisher Scientific, Waltham, MA, USA), and the purity of DNA was determined by Thermo Fisher Scientific’s NanoDrop One spectrophotometer. Extracted MB DNA was stored at −20 °C. Sequencing was performed using a NovaSeq PE150 (Illumina, San Diego, CA, USA). The 21 HPV GenoArray (GA) test (Hybribio Ltd., Hong Kong, China) was used for genotyping.

The investigators reported that the overall concordance rate of MB hrHPV capture sequencing and cervical HPV testing was 92.7, with a κ value of 0.763. Among 24 samples with incomplete concordance or discordant results, 11 samples with additional hrHPV genotypes (45.8%), five true-negative samples (20.8%), and the correct hrHPV genotypes of two samples (8.3%) were correctly identified by MB hrHPV capture sequencing. MB hrHPV detection of hrHPV was equivalent on different menstrual cycle days (MCDs), with an MB hrHPV–positive rate of 27/28 patients (96.4%) for MCD 1, 52/57 patients (91.2%) for MCD 2, 27/28 patients for MCD 3, 4/4 of patients (100%) for MCD 4, and 3/3 patients (100%) for MCD 5. The sensitivity of the MB hrHPV capture sequencing was 97.7%.

The authors concluded that MB hrHPV capture sequencing is a feasible and accurate self-collected approach for cervical cancer screening. This study found that this method is associated with superior performance in identification of HPV genotypes and true-negative events compared with cervical HPV testing. The study was published on December 23, 2021 in the journal JAMA Network Open.

Related Links:
Sun Yat-sen University
Central Hospital of Wuhan
Tiangen Biotech
Thermo Fisher Scientific
Hybribio Ltd

Gold Supplier
Nucleic Acid Extraction System
Multi-Tube Vortexer
BenchMixer XL
Automatic Nucleic Acid Purification System
GenePure Pro
Automated Molecular Diagnostic Analyzer
AutoMolec 1600

Print article
IIR Middle East


Molecular Diagnostics

view channel
Image: The ultrarapid genome sequencing pipeline, indicating all processes from sample collection to a diagnosis. Vertically stacked processes are run in parallel (Photo courtesy of Stanford University)

Ultrarapid Nanopore Genome Sequencing in a Critical Care Setting

A genetic diagnosis can guide clinical management and improve prognosis in critically ill patients, and much effort has gone into developing methods that result in rapid, reliable results.... Read more


view channel
Image: My Qualiris QC (Photo courtesy of Stago)

Stago Launches New My Qualiris QC Website for Brand-New User Experience

Stago (Paris, France) has launched its new My Qualiris QC website which provides a brand-new user experience with a 24/7 accessible web-application where the results of a user’s network are only a few clicks away.... Read more


view channel

Global Immunofluorescence Assay (IFA) Market to Surpass USD 4 Billion by 2028 Due to Growing Burden of Infectious Diseases

The global immunofluorescence assay (IFA) market is expected to reach USD 4.01 billion by 2028, driven by the increasing global healthcare burden of chronic and infectious diseases, rising application... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.